Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Leukemia|Lymphoma|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific
Interventions: BIOLOGICAL: filgrastim|DRUG: amifostine trihydrate|DRUG: cyclophosphamide|DRUG: melphalan|PROCEDURE: peripheral blood stem cell transplantation
Sponsor: University of Kentucky